57 results
8-K
EX-99.1
ATXI
Avenue Therapeutics, Inc.
9 Aug 24
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
4:13pm
privacy and security, and other healthcare laws and regulations; the effects of competition for our product candidates and the potential for new products
8-K
EX-99.1
ATXI
Avenue Therapeutics, Inc.
15 May 24
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9:01am
and future laws and regulations relating to fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare
424B3
ATXI
Avenue Therapeutics, Inc.
10 May 24
Prospectus supplement
4:53pm
of current and future laws and regulations relating to fraud and abuse, false claims, transparency, health information privacy and security, and other
424B5
7xinmfn4tk
10 May 24
Prospectus supplement for primary offering
4:52pm
8-K
EX-99.1
ryl8ukbd
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-99.1
etywnnf31 rtx
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
8-K
EX-99.1
8nmyz
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
424B3
uh1r8vf
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-10.2
77e3yui72g40
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
07j eya9rke3
2 Nov 23
Prospectus supplement with pricing info
9:00am
FWP
lwknpi3eqlc99y
5 Oct 23
Free writing prospectus
5:05pm
FWP
6k1iv2szc2cbo6
3 Oct 23
Free writing prospectus
5:47pm